Celltrion Healthcare starts to sell ‘Herzuma’ in Europe
Celltrion Healthcare announced on the 3rd that ‘Herzuma(generic name: trastuzumab),’ an antibody biosimilar for the treatment of breast cancer and stomach cancer, was first launched in the U.K. It is an early launch which was made only in 3 months of getting approval for Herzuma from the European...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
